Source - LSE Regulatory
RNS Number : 4562Y
Diurnal Group PLC
13 May 2021
 

13 May 2021

 

 

Diurnal Group plc

("Diurnal" or the "Company")

 

Correction: Director Dealings

 

This is a correction to the Director Dealings announcement published at 3:44 p.m. on 12 May 2021 (RNS number 4297Y) which has been amended with the correct total beneficial interests of Sam Williams, Interim Chairman and Richard Bungay, Chief Financial Officer each of 0.07% of the total voting rights.

 

Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, announces that further to the Capital Raising, details of which were announced on 21 April 2021 and Admission, the following Directors' dealings as part of the Subscription and Open Offer have completed:

 

Sam Williams, Interim Chairman, subscribed for 28,571 Ordinary Shares at a price of 70 pence per Ordinary Share.

Martin Whitaker, Chief Executive Officer, subscribed for a total of 10,000 Ordinary Shares at 70 pence per share, including 6,000 shares to be held in pension schemes for the beneficial interest of his dependent children.

Richard Bungay, Chief Financial Officer, subscribed for 7,143 Ordinary Shares at a price of 70 pence per Ordinary Share.

John Goddard, Non-Executive Director, subscribed for 28,571 Ordinary Shares at a price of 70 pence per Ordinary Share.

Following Admission, the total beneficial interest of Sam Williams is 113,819 Ordinary Shares, representing 0.07% of the total voting rights,  Martin Whitaker and his connected parties is 603,823 Ordinary Shares, representing 0.36% of the total voting rights, the total beneficial interest of Richard Bungay is 114,252 Ordinary Shares, representing 0.07% of the total voting rights and the total beneficial interest of John Goddard is 228,674 Ordinary Shares, representing 0.14% of the total voting rights. 

The capitalised terms used in this announcement have the same meanings as in the announcement published by the Company at 7.00 a.m. on 21 April 2021 unless otherwise stated.

Details of the full notifications received by the Company are set out below:

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Names

 

Sam Williams

Martin Whitaker and dependent children

Richard Bungay

John Goddard

2

 

Reason for the notification

 

a)

 

Position/status

 

Interim Chairman

Chief Executive Officer

Chief Financial Officer

Non-Executive Director

b)

 

Initial notification /Amendment

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

Diurnal Group plc

b)

 

LEI

 

213800I2HNUNZN1LDH29

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

Ordinary Shares of 5 pence each in Diurnal Group plc



Identification code

GB00BDB6Q760



b)

 

Nature of the transaction

 

Purchase of Ordinary Shares 

c)

 

Price(s) and volume(s)







Price(s)

Volume(s)




70p

28,571




70p

10,000




70p

7,143




70p

28,571







d)

 

Aggregated information




- Aggregated volume

n/a



- Price




e)

 

Date of the transaction

 

11 May 2021

f)

 

Place of the transaction

 

XLON

 

For further information, please visit www.diurnal.co.uk or contact:



Diurnal Group plc

+44 (0)20 3727 1000

Martin Whitaker, Chief Executive Officer


Richard Bungay, Chief Financial Officer




Panmure Gordon (UK) Limited (Nominated Adviser and Sole Broker)

+44 (0)20 7886 2500

Corporate Finance: Freddy Crossley, Emma Earl


Corporate Broking: Rupert Dearden




FTI Consulting (Media and Investor Relations)

+44 (0)20 3727 1000

Simon Conway


Victoria Foster Mitchell


Alex Davis


 

 

Notes to Editors

 

About Diurnal Group plc

Diurnal Group plc is a European, UK-headquartered, specialty pharmaceutical company dedicated to developing hormone therapeutics to aid lifelong treatment for rare and chronic endocrine conditions, including congenital adrenal hyperplasia, adrenal insufficiency, hypogonadism and hypothyroidism. Its expertise and innovative research activities focus on circadian-based endocrinology to yield novel product candidates in the rare and chronic endocrine disease arena.

 

For further information about Diurnal, please visit www.diurnal.co.uk

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHBCGDUXDBDGBD
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account. AJBell logo

Related Charts